Adding cabozantinib to first-line treatment with ipilimumab plus nivolumab improved progression-free survival in patients with advanced, intermediate- or poor-risk renal cell carcinoma.
Combination treatment with belzutifan and cabozantinib has demonstrated antitumor activity in previously treated, advanced clear cell renal cell carcinoma.
Avelumab plus cabozantinib has shown preliminary clinical activity and an acceptable safety profile in metastatic clear cell RCC, according to researchers.
The conversion from accelerated approval to regular approval was based on data from the KEYNOTE-158 trial, the KEYNOTE-164 trial, and the KEYNOTE-051 trial.
Partial vs radical cytoreductive nephrectomy for clear cell metastatic renal cell carcinoma was associated with a 54% decreased risk for other-cause mortality.
Investigators concluded that pN1 RCC could be stratified into pN1 and pN2, with pN2 conferring a poor prognosis comparable to that of non-metastatic stage IV pN0 disease.